$51.83
-0.16-0.31%
Last update: Nov 11, 7:11 AM
Travere Therapeutics Inc
TVTXNASDAQ
Travere Therapeutics rose 44.0% from $36.11 to $51.99, ahead of the S&P 500's +9.8%. Its worst day was Jan 13 (−14.6%), and its low came Mar 24 at $26.79.
Nov 11, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Travere Therapeutics shares rose 13.9%, while the S&P 500 rose 0.4%.
+13.9% · S&P 500 +0.4%
Story events cover the past 12 months · Times ET
Travere Therapeutics shares fell 14.6%, while the S&P 500 fell 0.2%.
−14.6%, the year's worst day, on 20M shares, the year's heaviest volume · S&P 500 −0.2%
EPS of $0.37 beat the $0.24 estimate on $129.7M revenue (est. $145.6M).
+3.7% · S&P 500 +0.7%
Travere Therapeutics closed at its lowest level of the year, 25.8% below where the year started.
−3.5% · S&P 500 −0.3%
Travere Therapeutics shares rose 37.2%, while the S&P 500 rose 1.2%.
+37.2%, the year's best day · S&P 500 +1.2%
EPS of $0.05 beat the $-0.10 estimate on $127.2M revenue (est. $135.3M).
−0.2% · S&P 500 +0.8%
EPS of $-0.10 missed the $0.23 estimate on $169.6M revenue (est. $159.3M).
+12.0% · S&P 500 −0.2%
Travere Therapeutics closed at its highest level of the year, 87.0% above where the year started.
+0.6% · S&P 500 +0.7%
EPS of $-0.31 missed the $0.28 estimate on $224.6M revenue (est. $194.7M).
+0.3% · S&P 500 +0.3%
Where it ended: a close of $51.99 on Nov 10, 2026. Up next: Q4 2026 earnings on Feb 18, 2027 (EPS est. $0.91, revenue est. $252.5M).
Nothing in the past 12 months.
All TVTX dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for TVTX and SPY from Benzinga historical bars. Not investment advice.
